Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis

Background The average age of patients diagnosed with renal cell carcinoma (RCC) is increasing, but a limited number of reports have described therapy of tyrosine kinase inhibitor for elderly RCC patients. Hence, we analysed the efficacy and safety of sorafenib in elderly patients aged ≥75 years wit...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2018-07, Vol.119 (2), p.241-247
Main Authors: Tatsugami, Katsunori, Oya, Mototsugu, Kabu, Koki, Akaza, Hideyuki
Format: Article
Language:English
Subjects:
692/4028/67/1059/602
692/699/67/589/1588/1351
Biomedical and Life Sciences
Biomedicine
Cancer Research
Demographics
Demography
Drug Resistance
Enzyme inhibitors
Epidemiology
Geriatrics
Inhibitor drugs
Kidney cancer
Medical prognosis
Molecular Medicine
Older people
Oncology
Patients
Protein-tyrosine kinase
Renal cell carcinoma
Renal function
Safety
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The average age of patients diagnosed with renal cell carcinoma (RCC) is increasing, but a limited number of reports have described therapy of tyrosine kinase inhibitor for elderly RCC patients. Hence, we analysed the efficacy and safety of sorafenib in elderly patients aged ≥75 years with advanced RCC. Methods Data were extracted from
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-018-0129-3